阿米卡星/头孢吡肟(Amikacin/Cefepime) - 药物靶点：30S subunit x PBPs_在研适应症：粒细胞减少性发热，医疗保健相关性肺炎_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Potentox

靶点

30S subunit x PBPs

作用机制

30S subunit抑制剂(30S核糖体亚基抑制剂)、PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)、细胞壁抑制剂

治疗领域

感染血液及淋巴系统疾病呼吸系统疾病

在研适应症

粒细胞减少性发热医疗保健相关性肺炎

非在研适应症-

原研机构

Venus Remedies Ltd.

在研机构

Venus Remedies Ltd.

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C19H24N6O5S2

InChIKeyHVFLCNVBZFFHBT-ZKDACBOMSA-N

CAS号88040-23-7

查看全部结构式(2)

关联

2

项与阿米卡星/头孢吡肟相关的临床试验

NCT02084043 / CompletedN/AIIT

In Vitro Comparison of Continuous and Breath-synchronized Vibrating Mesh Nebulizer During Non Invasive Ventilation: Analysis of Inhaled and Lost Doses.

Using an adult lung bench model of non invasive ventilation, the aim of the study is to compare an experimental system of breath-synchronized vibrating mesh nebulizer to a conventional vibrating mesh nebulizer during non invasive ventilation in terms of inhaled and lost doses.

开始日期2014-03-01

申办/合作机构

School of Gestion and Engineering Vaud, Switzerland

[+1]

NCT01315236 / Completed临床2期

A Randomized, Double-Blind, Placebo-Controlled Study of Liposomal Amikacin for Inhalation in Patients With Recalcitrant Nontuberculous Mycobacterial Lung Disease

The purpose of this study is to evaluate the efficacy, safety and tolerability of 84 days of daily dosing of 590 mg of LAI versus placebo in patients with treatment refractory NTM lung disease.
The first part of the study is the 84-day double-blind phase to evaluate the primary and secondary endpoints.

开始日期2012-04-19

申办/合作机构

Insmed, Inc.

[+1]

100 项与阿米卡星/头孢吡肟相关的临床结果

登录后查看更多信息

100 项与阿米卡星/头孢吡肟相关的转化医学

登录后查看更多信息

100 项与阿米卡星/头孢吡肟相关的专利（医药）

登录后查看更多信息

2

项与阿米卡星/头孢吡肟相关的文献（医药）

2009-01-01·Experimental Lung Research4区 · 医学

FIXED-DOSE COMBINATION OF CEFEPIME PLUS AMIKACIN (POTENTOX) INHIBITS PNEUMONIA INFECTION

4区 · 医学

Article

作者: Soni A ; Dwivedi Vk ; Chaudhary M ; Shrivastava Sm ; Singh Cp

Pneumonia is a severe infection that causes high morbidity and mortality rate worldwide. It is caused by Klebsiella pneumoniae, which generally causes upper respiratory tract infection. In case of such type of infection, levels of oxidant and antioxidant become imbalanced, which may contribute to lung injury. The present study was planned to evaluate the status of oxidant and antioxidant enzyme activities in plasma and lung tissue of pneumonia-infected rats model. Animals were randomly distributed into 3 groups of 8 rats each: groups I (control, normal saline treated), II (infected group), and III (infected + treated group). The findings showed that there was significant increase (P < .001) in body temperature along with decreased body weight in the infected group as compared to the control group. Similarly, all the activities of antioxidant enzymes (superoxide dismutase [SOD], catalase) were significantly decreased along with increased malonaldialdehyde (MDA) levels in plasma and lung tissue of the infected group as compared to the control group. These enzyme activities along with MDA levels were improved and came back near to normal level after administration of cefepime plus amikacin (potentox) for 7 days in group III. These studies concluded that fixed-dose combination of potentox improved oxidant and antioxidant levels in pneumonia infection.

2008-09-01·Current Clinical Pharmacology

Fixed Dose Combination of Cefepime Plus Amikacin Prevent Oxidative Stress in Liver of Mus musculus Mice

Article

作者: Soni, Arvind ; Chaudhary, Manu ; Dwivedi, Vivek Kumar

Oxidative stress and free radical are causative factors for aminoglycoside induced tissue injury. The objective of present study was to evaluate effect of fixed dose combination of cefepime + amikacin on antioxidant enzymes such as superoxide dismutase (SOD), catalase along with malonaldialdehyde (MDA) levels in liver of Mus musculus mice. Our findings showed that the activities of the antioxidant enzymes such as superoxide dismutase (p<0.001, 62.2%), catalase (p<0.05, 47.5%) were significantly lowered along with increase in the MDA levels (66.0%) after the single treatment of amikacin as compared to control group. A significant improvement in the activities of superoxide dismutase and catalase along with decrease in MDA levels were observed in fixed dose combination of cefepime plus amikacin treated groups as compared to amikacin alone treated group. These findings suggest that the fixed dose combination therapy of cefepime + amikacin (Potentox) show significant free radical scavenging property which may contribute to decrease in aminoglycoside induced liver injury.

100 项与阿米卡星/头孢吡肟相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	J01RA06	-

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
粒细胞减少性发热	-	Venus Remedies Ltd.	-
医疗保健相关性肺炎	-	Venus Remedies Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01315236 (CTgov)	临床2期	非结核分枝杆菌感染	90	Liposomal amikacin for inhalation (LAI) (LAI 590 mg QD)	獵餘遞淵壓廠餘壓網顧(鏇願獵觸鑰鹹顧顧鹹網) = 衊醖網鬱觸夢夢鹹艱願襯鏇醖遞蓋獵齋蓋齋鑰 (壓膚蓋壓膚壓餘選構範, 鹹衊製範淵鏇簾願壓繭 ~ 膚憲鹹窪窪淵遞艱膚襯) 更多	-	2019-08-21
				placebo (Placebo)	獵餘遞淵壓廠餘壓網顧(鏇願獵觸鑰鹹顧顧鹹網) = 顧積鏇鹽憲築窪遞積網襯鏇醖遞蓋獵齋蓋齋鑰 (壓膚蓋壓膚壓餘選構範, 糧齋製糧憲壓繭壓製壓 ~ 製淵蓋築餘選糧醖膚餘) 更多